Single-cell analysis reveals IGF-1 potentiation of inhibition of the TGF-β/Smad pathway of fibrosis in human keratocytes in vitro.
Corneal wound healing is often affected by TGF-β-mediated fibrosis and scar formation. Guided fibrosis with IGF-1 and antifibrotic substances might maintain corneal transparency. Primary human corneal keratocytes under serum-free conditions were used as a model of corneal stromal wounding, with markers of corneal fibrosis and opacity studied under TGF-β2 stimulation. Single-cell imaging flow cytometry was used to determine nuclearization of Smad3, and intracellular fluorescence intensity of Smad7 and the corneal crystallin aldehyde dehydrogenase 3A1. Extracellular matrix proteoglycans keratocan and biglycan were quantified using ELISAs. On the TGF-β2 background, the keratocytes were treated with IGF-1, and suberoylanilidehydroxamic acid (SAHA) or halofuginone ± IGF-1. IGF-1 alone decreased Smad3 nuclearization and increased aldehyde dehydrogenase 3A1 expression, with favorable extracellular matrix proteoglycan composition. SAHA induced higher Smad7 levels and inhibited translocation of Smad3 to the nucleus, also when combined with IGF-1. Immunofluorescence showed that myofibroblast transdifferentiation is attenuated and appearance of fibroblasts is favored by IGF-1 alone and in combination with the antifibrotic substances. The TGF-β/Smad pathway of fibrosis and opacity was inhibited by IGF-1, and further with SAHA in particular, and with halofuginone. IGF-1 is thus a valid aid to antifibrotic treatment, with potential for effective and transparent corneal wound healing.
Department of Ophthalmology, University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia.|Institute of Physiology, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Tomislav
T
Sarenac
Institute of Physiology, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.|Gladstone Institute of Virology and Immunology, University of California, 1650 Owens Street, 94158 San Francisco, CA, USA.
Martin
M
Trapecar
Institute of Physiology, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Lidija
L
Gradisnik
Institute of Physiology, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.|Institute of Physiology, Centre for Physiology and Pharmacology, Medical University of Vienna, Währingerstrasse 13A, 1090 Vienna, Austria.
Marjan Slak
MS
Rupnik
Department of Ophthalmology, University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia.|Institute of Physiology, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Dusica
D
Pahor
FEBS J. 2013 May;280(10 ):2120-37
23331954
Arch Biochem Biophys. 1992 Jul;296(1):190-7
1605630
Mol Cancer Ther. 2007 Feb;6(2):570-7
17267660
Prog Retin Eye Res. 1999 May;18(3):311-56
10192516
Vet Ophthalmol. 2016 Nov;19(6):480-487
26559782
Invest Ophthalmol Vis Sci. 2003 May;44(5):1850-8
12714615
Curr Drug Targets. 2010 Nov;11(11):1430-8
20583972
Nat Biotechnol. 2007 Jan;25(1):84-90
17211407
J Cell Biol. 1998 Jun 1;141(5):1277-86
9606218
Exp Eye Res. 2002 Dec;75(6):645-57
12470966
Brain Res Bull. 2010 Feb 15;81(2-3):198-210
19481138
Curr Mol Med. 2010 Aug;10(6):565-78
20642439
J Muscle Res Cell Motil. 2014 Dec;35(5-6):249-57
25380573
J Biol Chem. 2004 Apr 9;279(15):15167-76
14732719
Biol Blood Marrow Transplant. 2003 Jul;9(7):417-25
12869955
Exp Eye Res. 2016 Jan;142:40-8
26675402
J Biol Chem. 2003 Nov 14;278(46):45629-37
12933807
J Cell Physiol. 2010 Jul;224(1):135-43
20232294
J Cell Biochem. 2009 Oct 1;108(2):476-88
19626665
Invest Ophthalmol Vis Sci. 2012 Feb 16;53(2):770-8
22247459
J Biol Chem. 2001 Nov 23;276(47):44173-8
11555658
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3128-36
19234354
Matrix Biol. 2014 Apr;35:103-11
24447998
Vet Ophthalmol. 2014 Jul;17 Suppl 1:61-8
25126665
Semin Cell Dev Biol. 2008 Apr;19(2):82-93
17997336
Eye Contact Lens. 2010 Sep;36(5):286-9
20823707
Exp Eye Res. 2010 Sep;91(3):326-35
20599432
J Cell Physiol. 2005 Apr;203(1):226-32
15521071
Exp Eye Res. 2007 Jan;84(1):3-12
16797007
Sci Rep. 2015 Jun 03;5:10839
26039975
Chin Med J (Engl). 2011 Jul 5;124(13):1988-93
22088458
Exp Eye Res. 2004 Nov;79(5):705-12
15500828
Exp Eye Res. 2004 Mar;78(3):553-60
15106935
Invest Ophthalmol Vis Sci. 2009 Feb;50(2):634-43
18952913
Invest Ophthalmol Vis Sci. 2012 May 14;53(6):2786-95
22467580
Exp Eye Res. 2006 Nov;83(5):1063-73
16822507
Exp Eye Res. 2012 Jun;99:78-88
22542905
Matrix Biol. 2010 Jul;29(6):519-24
20580823
Prog Retin Eye Res. 2008 Mar;27(2):177-96
18243038
Exp Eye Res. 2006 May;82(5):788-97
16303127
J Biol Chem. 2005 Jun 10;280(23):21797-803
15831498
Prog Retin Eye Res. 2015 Nov;49:1-16
26145225
Eye (Lond). 2005 Oct;19(10):1133-5
16304595
Matrix Biol. 2000 Dec;19(7):693-8
11102758
Mol Pharm. 2013 Jan 7;10(1):307-18
23186311
Acta Biochim Biophys Sin (Shanghai). 2009 Apr;41(4):263-72
19352540
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4237-46
14507867
Int J Exp Pathol. 2004 Apr;85(2):47-64
15154911
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3365-73
11006226
Exp Eye Res. 2016 Jan;142:110-8
26675407
J Biol Chem. 1997 Oct 31;272(44):28089-95
9346963
Biochem Biophys Res Commun. 2015 Aug 21;464(2):596-602
26151859
Am J Physiol Endocrinol Metab. 2013 Aug 1;305(3):E367-75
23736539
Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70
19700647
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10 ):7647-53
20631235
PLoS One. 2014 Jan 16;9(1):e86297
24454965
J Biol Chem. 2003 Oct 3;278(40):38342-51
12876289
Chin Med J (Engl). 2013;126(8):1445-50
23595375
Mol Vis. 2012;18:479-87
22393274
Exp Cell Res. 2010 Apr 1;316(6):1061-9
20060825
J Refract Surg. 2012 Apr;28(4):285-90
22386369